The Global Retinal Biologics Industry is on the brink of a transformative journey, exhibiting remarkable growth with a projected value exceeding US$22.25 billion by 2022. This upward trajectory is set to surge even further, reaching a staggering US$41.92 billion by 2028, propelled by an impressive Compound Annual Growth Rate (CAGR) of 11.1% between 2022 and 2028, as revealed by recent insights from Future Market Insights Inc.
The expansion of the Global Retinal Biologics sector is nothing short of spectacular, driven by the confluence of technological advancements, groundbreaking research, and an escalating demand for cutting-edge treatments. This industry’s evolution not only signifies progress in healthcare but also opens unprecedented opportunities for stakeholders, investors, and healthcare professionals worldwide.
Key Global Retinal Biologics Industry Insights:
- Rising Prevalence of Diabetes-related Eye Disorders and Age-related Macular Degeneration (AMD) The prevalence of diabetes-related eye disorders and age-related macular degeneration is on the rise, underscoring the growing need for innovative solutions within the Retinal Biologics Industry.
- Substantial Investment in R&D for Biologics in Retinal Disorders The industry is witnessing a significant influx of research and development resources, aimed at advancing biologics for both infectious and non-infectious retinal disorders. This investment underscores the commitment to addressing unmet medical needs.
- Emergence of Specific Biologic Molecules as Therapeutic Targets Specific biologic molecules are gaining prominence as highly promising therapeutic targets, offering new hope for patients with retinal conditions.
- Gene Therapy as a Solution for Monogenic Retinal Illnesses With a growing number of monogenic retinal illnesses, gene therapy is emerging as a pivotal component of the Retinal Biologics Market, presenting innovative solutions for these challenging conditions.
Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-8663
Retinal Biologics Distribution in Specialty Clinics and Hospitals Prominent
Retinal Biologics manufacturers offer their goods through institutional and retail distribution channels. According to the FMI report, institutional sales in the Retinal Biologics Industry, where Retinal Biologics are supplied in speciality clinics and hospitals, will generate higher revenues. In 2018, hospital sales accounted for more than 35% of market revenue.
According to the report, retail sales of Retinal Biologics will generate comparable revenues to hospital sales and will expand at an 11.9% annual rate in 2019. Retail distribution takes place through retail pharmacies and mail order pharmacies, with retail pharmacies generating more money than their counterparts in the future years.
Penetration in North America Higher, APEJ’s Attractiveness to Increase
North America continues to be the market leader in Retinal Biologics revenue. According to FMI estimates, North America accounted for more than 46% of global Retinal Biologics Industry revenues in 2018. Revenues in North America are predicted to expand 10.4% year on year in 2019 due to an increase in the prevalence of retinal illnesses, continuous growth in the healthcare infrastructure, and a favourable reimbursement scenario.
Europe accounted for about one-fourth of the Retinal Biologics market, with Western European countries such as Germany, the United Kingdom, France, Italy, and Spain accounting for the majority of demand penetration. The APEJ Retinal Biologics Industry is predicted to grow at an 11% annual rate in 2019, with China and India remaining the most lucrative areas.
Ask an analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-8663
Retinal Biologics Find Prominent Use in Macular Degeneration Treatment
The study opines that over 35% of the Retinal Biologics revenues were consolidated in the treatment of macular degeneration. Highest revenue growth of 12.3% is also expected in macular degeneration as compared to other indications where Retinal Biologics are used in 2019.
Macular degeneration (MD) remains the leading cause of vision loss wherein it affects over 10 million Americans, the prevalence is higher than the combined incidences of cataracts and glaucoma, as per the American Macular Degeneration Foundation (AMDF). As macular degeneration mainly affects people of age 50 years or more, with the ageing population, the prevalence of MD continues to rise despite improved treatment options.
Key Players Covered In The Global Retinal Biologics Industry:
- Spark Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- Amgen Inc.
- Novartis Pharma AG
- MeiraGTx Limited
- Oxurion NV
- Santen Pharmaceutical Co., Ltd.
- Bayer AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
Level Up Your Market Understanding – Buy Now!
https://www.futuremarketinsights.com/checkout/8663
Key Segments of Global Retinal Biologics Industry Survey
Global Retinal Biologics Industry by Drug Class:
- VEGF-A Antagonists
- TNF-α Inhibitors
Global Retinal Biologics Industry by Indication:
- Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Uveitis
- Others
Global Retinal Biologics Industry by Distribution Channel:
- Institutional Sales
- Retail Pharmacies
- Mail Order Pharmacies
- Retail Sales
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube